The 10-second takeaway
For the quarter ended Sep. 28 (Q3), STAAR Surgical missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share was unchanged.
Gross margins increased, operating margins shrank, net margins shrank.
STAAR Surgical logged revenue of $15.9 million. The six analysts polled by S&P Capital IQ anticipated a top line of $16.9 million on the same basis. GAAP reported sales were 3.9% higher than the prior-year quarter's $15.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.04. The two earnings estimates compiled by S&P Capital IQ averaged $0.03 per share. GAAP EPS of $0.00 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 70.4%, 190 basis points better than the prior-year quarter. Operating margin was -0.6%, 540 basis points worse than the prior-year quarter. Net margin was -0.6%, 110 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $18.8 million. On the bottom line, the average EPS estimate is $0.04.
Next year's average estimate for revenue is $67.2 million. The average EPS estimate is $0.08.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 90 members out of 99 rating the stock outperform, and nine members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give STAAR Surgical a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is buy, with an average price target of $9.65.
- Add STAAR Surgical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
5 of Last Week's Biggest Losers
These five stocks suffered double-digit percentage declines last week.
3 Stocks Crushed by the Market This Week
No pops and sizzles for these stocks. Just drops and fizzles.
Why STAAR Surgical Company Shares Are Seeing Big Gains
STAAR Surgical surges after a positive FDA panel review. Can shares head even higher?